SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.67

13 Apr
2026

-0.020

OPEN

$2.71

-0.74%

HIGH

$2.72

9,185,194

LOW

$2.66

TARGET
$3.23 21.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 5.1 6.3 xxx
DPS (cps) xxx 1.8 4.1 xxx
EPS Growth xxx 100.0% 25.3% xxx
DPS Growth xxx 82.7% 100.0% xxx
PE Ratio xxx N/A 42.7 xxx
Dividend Yield xxx N/A 1.5% xxx
Div Pay Ratio(%) xxx 35.6% 64.7% xxx

Dividend yield today if purchased 3 years ago: 2.54%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.66

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx5.1
DPS All xxxxxxxxxxxxxxx1.8
Sales/Revenue xxxxxxxxxxxxxxx14,404.4 M
Book Value Per Share xxxxxxxxxxxxxxx40.6
Net Operating Cash Flow xxxxxxxxxxxxxxx598.8 M
Net Profit Margin xxxxxxxxxxxxxxx8.83 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-
Return on Assets xxxxxxxxxxxxxxx-
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-
Free Cash Flow ex dividends xxxxxxxxxxxxxxx60.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx194 M
Long Term Debt xxxxxxxxxxxxxxx1,877 M
Total Debt xxxxxxxxxxxxxxx2,071 M
Goodwill - Gross xxxxxxxxxxxxxxx3,617 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx139 M
Price To Book Value xxxxxxxxxxxxxxx7.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx57.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx10,948 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,606 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx80 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

27/02/2026

3

Neutral

$3.20

19.85%

Evident from Sigma Healthcare's interim result, Citi explains revenue continues to positively surprise, though the outperformance is being supported by lower-margin GLP-1 products. It's felt the latter is constraining operating leverage.

The broker suggests the next phase of the investment case will depend on further geographic expansion and evidence that Ireland and Dubai can replicate New Zealand’s successful trajectory.

Neutral rating and $3.20 target retained.

See below for a summary of the analyst's initial research on the interim results.

Sigma Healthcare today reported 1H26 normalised earnings (EBIT) of $583m, in line with the consensus estimate but ahead of Citi’s $554m forecast. Both revenue and margins came in above the broker’s expectations.

In an early assessment, the analysts highlight stronger-than-expected Chemist Warehouse Australian like-for-like sales growth of 15%, accelerating on FY25.

Domestically there were 13 net store additions and 11 internationally. New Zealand sales rose by 22.4% and Ireland's jumped 49.6%.

Owned and exclusive label sales rose 15.7% and the $100m synergy target remains on track, according to Citi, with $13m realised in H1.

The broker notes early H2 trading remains strong, with Chemist Warehouse network sales up 16.6%.

An interim dividend of 2c was declared.

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

05/03/2026

1

Upgrade to Buy from Overweight

$3.60

34.83%

Sigma Healthcare posted first half earnings that were in line with expectations albeit the composition was different to what Jarden anticipated. Sales were ahead of forecasts while margin expansion was softer.

Going forward, the broker surmises the risks are to the upside for earnings with the international roll-out and synergies on track. The main challenge is to confidently forecast revenue outcomes going forward, as well as leverage. 

Forecasts are largely unchanged and the broker, liking the health exposure, market position and high incremental returns on capital, upgrades to Buy from Overweight. Target of $3.60 is unchanged.

FORECAST
Jarden forecasts a full year FY26 dividend of 3.80 cents and EPS of 6.40 cents.
Jarden forecasts a full year FY27 dividend of 4.60 cents and EPS of 7.70 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

1
The Defensive Proposition Of Sigma Healthcare

Mar 30 2026 - Australia
2
Weekly Ratings, Targets, Forecast Changes – 27-03-26

Mar 30 2026 - Weekly Reports
3
Rudi’s View: Make Today’s Crisis Your Opportunity

Mar 25 2026 - Rudi's View
4
Rudi’s View: Top Picks & Conviction Buys

Mar 19 2026 - Rudi's View
5
Rudi’s View: Oil, Inflation, Growth & Stagflation

Mar 18 2026 - Rudi's View

Latest Health & Nutrition News

1
The Defensive Proposition Of Sigma Healthcare

Mar 30 2026 - Australia
2
Sigma Healthcare’s Four Pillars Of Growth

Aug 29 2025 - Australia
3
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
4
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
5
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
6
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
7
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
8
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
9
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
10
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI